Horizons in therapy for corneal angiogenesis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21376242.
- Also identified by DOI 10.1016/j.ophtha.2011.01.041 and PMC identifier 4107641.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Corneal neovascularization can lead to a devastating disease process that involves the breakdown of the limbal barrier and the formation of blood vessels in the cornea, leading to severe visual impairment. This review discusses the delicate balance between antiangiogenic and angiogenic factors that govern the antiangiogenic privilege of the cornea. Current treatment methods, clinical trials, and future prospects in the management of corneal neovascularization also are discussed.
Medical subject headings
- Angiogenesis Inhibitors
- Corneal Neovascularization